Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(248,509) | $(374,384) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 37,840 | 43,180 |
| Stock-based compensation | 41,713 | 62,217 |
| Asset impairment | — | 5,956 |
| Lease expense | 10,459 | 11,755 |
| Loss on disposal of a business | — | 4,502 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s D&A?
- Recursion Pharmaceuticals, Inc. (RXRX) reported D&A of $18.17M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s D&A decreased by 23.8% year-over-year, from $23.85M to $18.17M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s D&A has grown at a 77.6% compound annual growth rate (CAGR), from $8.41M to $83.7M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Recursion Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude